There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment
of postmenopausal osteoporosis and prevention of skeletal metastasis complications.
Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture
by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may
be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture
activity equivalent to that of zoledronic acid, but no residual effect, and no action
at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment
after a first attempt with bisphosphonate.